Limits...
Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges.

Basavaraj S, Betageri GV - Acta Pharm Sin B (2014)

Bottom Line: Drug discovery and development has become longer and costlier process.The fear of failure and stringent regulatory review process is driving pharmaceutical companies towards "me too" drugs and improved generics (505(b) (2)) fillings.The formulation and drug delivery technologies are suitable for addressing various issues contributing to attrition are discussed in detail.

View Article: PubMed Central - PubMed

Affiliation: Western Centre for Drug Development, Western University of Health Sciences, Pomona, CA 91766, USA.

ABSTRACT
Drug discovery and development has become longer and costlier process. The fear of failure and stringent regulatory review process is driving pharmaceutical companies towards "me too" drugs and improved generics (505(b) (2)) fillings. The discontinuance of molecules at late stage clinical trials is common these years. The molecules are withdrawn at various stages of discovery and development process for reasons such as poor ADME properties, lack of efficacy and safety reasons. Hence this review focuses on possible applications of formulation and drug delivery to salvage molecules and improve the drugability. The formulation and drug delivery technologies are suitable for addressing various issues contributing to attrition are discussed in detail.

No MeSH data available.


© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4590717&req=5


Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges.

Basavaraj S, Betageri GV - Acta Pharm Sin B (2014)

© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4590717&req=5

Bottom Line: Drug discovery and development has become longer and costlier process.The fear of failure and stringent regulatory review process is driving pharmaceutical companies towards "me too" drugs and improved generics (505(b) (2)) fillings.The formulation and drug delivery technologies are suitable for addressing various issues contributing to attrition are discussed in detail.

View Article: PubMed Central - PubMed

Affiliation: Western Centre for Drug Development, Western University of Health Sciences, Pomona, CA 91766, USA.

ABSTRACT
Drug discovery and development has become longer and costlier process. The fear of failure and stringent regulatory review process is driving pharmaceutical companies towards "me too" drugs and improved generics (505(b) (2)) fillings. The discontinuance of molecules at late stage clinical trials is common these years. The molecules are withdrawn at various stages of discovery and development process for reasons such as poor ADME properties, lack of efficacy and safety reasons. Hence this review focuses on possible applications of formulation and drug delivery to salvage molecules and improve the drugability. The formulation and drug delivery technologies are suitable for addressing various issues contributing to attrition are discussed in detail.

No MeSH data available.